COMBINATION OF 600 MG TELBIVUDINE DAILY, WITH PEGYLATED INTERFERON ALFA-2A, 180 MICROGRAMS ONCE WEEKLY BY SUBCUTANEOUS ADMINISTRATION MAY BE ASSOCIATED WITH AN INCREASED RISK OF PERIPHERAL NEUROPATHY OCCURRENCE AND SEVERITY, IN COMPARISON TO TELBIVUDINE ALONE.